These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 20938170)

  • 1. Sorafenib treatment in 13 patients with acute myeloid leukemia and activating FLT3 mutations in combination with chemotherapy or as monotherapy.
    Schroeder T; Zohren F; Saure C; Bruns I; Czibere A; Safaian NN; Fenk R; Haas R; Kobbe G
    Acta Haematol; 2010; 124(3):153-9. PubMed ID: 20938170
    [No Abstract]   [Full Text] [Related]  

  • 2. Complete resolution of leukemia cutis with sorafenib in an acute myeloid leukemia patient with FLT3-ITD mutation.
    Lee SH; Paietta E; Racevskis J; Wiernik PH
    Am J Hematol; 2009 Oct; 84(10):701-2. PubMed ID: 19714594
    [No Abstract]   [Full Text] [Related]  

  • 3. Secondary resistance to sorafenib in two patients with acute myeloid leukemia (AML) harboring FLT3-ITD mutations.
    Scholl S; Spies-Weisshart B; Klink A; Muegge LO; Fricke HJ; Hochhaus A
    Ann Hematol; 2011 Apr; 90(4):473-5. PubMed ID: 20652568
    [No Abstract]   [Full Text] [Related]  

  • 4. Marked bone marrow hypoplasia associated with sorafenib-induced marrow blast clearance in two patients with FLT3-ITD acute myeloid leukemia.
    Fesler MJ
    Leuk Res; 2011 Mar; 35(3):e21-2. PubMed ID: 21144585
    [No Abstract]   [Full Text] [Related]  

  • 5. A case of blast clearance on sorafenib in relapsed FLT3-ITD acute myeloid leukemia: evidence of efficacy continues to mount.
    Fesler MJ; Richart JM; Petruska PJ
    Leuk Res; 2010 Oct; 34(10):e268-9. PubMed ID: 20417967
    [No Abstract]   [Full Text] [Related]  

  • 6. Sorafenib treatment of FLT3-ITD(+) acute myeloid leukemia: favorable initial outcome and mechanisms of subsequent nonresponsiveness associated with the emergence of a D835 mutation.
    Man CH; Fung TK; Ho C; Han HH; Chow HC; Ma AC; Choi WW; Lok S; Cheung AM; Eaves C; Kwong YL; Leung AY
    Blood; 2012 May; 119(22):5133-43. PubMed ID: 22368270
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Use of Sorafenib as an effective treatment in an AML patient carrying a new point mutation affecting the Juxtamembrane domain of FLT3.
    Martínez-López J; Castro N; Rueda D; Canal A; Grande C; Ayala R
    Br J Haematol; 2012 Aug; 158(4):555-8. PubMed ID: 22686329
    [No Abstract]   [Full Text] [Related]  

  • 8. Sorafenib for refractory FMS-like tyrosine kinase receptor-3 (FLT3/ITD+) acute myeloid leukemia after allogenic stem cell transplantation.
    Sorà F; Chiusolo P; Metafuni E; Bellesi S; Giammarco S; Laurenti L; Ausoni G; Zini G; Bayer AJ; Mario B; Leone G; Sica S
    Leuk Res; 2011 Mar; 35(3):422-3. PubMed ID: 21093053
    [No Abstract]   [Full Text] [Related]  

  • 9. High activity of sorafenib in FLT3-ITD-positive acute myeloid leukemia synergizes with allo-immune effects to induce sustained responses.
    Metzelder SK; Schroeder T; Finck A; Scholl S; Fey M; Götze K; Linn YC; Kröger M; Reiter A; Salih HR; Heinicke T; Stuhlmann R; Müller L; Giagounidis A; Meyer RG; Brugger W; Vöhringer M; Dreger P; Mori M; Basara N; Schäfer-Eckart K; Schultheis B; Baldus C; Neubauer A; Burchert A
    Leukemia; 2012 Nov; 26(11):2353-9. PubMed ID: 22504140
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Sorafenib monotherapy gives sustainable suppression of FLT3 clone in untreated patients with FLT3-internal tandem duplication positive acute myeloid Leukaemia.
    Mohan BP; How GF; Loh Y; Linn YC
    Br J Haematol; 2012 Apr; 157(1):131-2. PubMed ID: 22050655
    [No Abstract]   [Full Text] [Related]  

  • 11. Sorafenib (Nexavar) induces molecular remission and regression of extramedullary disease in a patient with FLT3-ITD+ acute myeloid leukemia.
    Safaian NN; Czibere A; Bruns I; Fenk R; Reinecke P; Dienst A; Haas R; Kobbe G
    Leuk Res; 2009 Feb; 33(2):348-50. PubMed ID: 18573526
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Treatment of FLT3-ITD-positive acute myeloid leukemia relapsing after allogeneic stem cell transplantation with sorafenib.
    Sharma M; Ravandi F; Bayraktar UD; Chiattone A; Bashir Q; Giralt S; Chen J; Qazilbash M; Kebriaei P; Konopleva M; Andreeff M; Cortes J; McCue D; Kantarjian H; Champlin RE; de Lima M
    Biol Blood Marrow Transplant; 2011 Dec; 17(12):1874-7. PubMed ID: 21767516
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Sorafenib induces sustained molecular remission in FLT3-ITD positive AML with relapse after second allogeneic stem cell transplantation without exacerbation of acute GVHD: a case report.
    Winkler J; Rech D; Kallert S; Rech J; Meidenbauer N; Roesler W; Mackensen A
    Leuk Res; 2010 Oct; 34(10):e270-2. PubMed ID: 20627386
    [No Abstract]   [Full Text] [Related]  

  • 14. FLT3 inhibitors for the treatment of acute myeloid leukemia.
    Wiernik PH
    Clin Adv Hematol Oncol; 2010 Jun; 8(6):429-36, 444. PubMed ID: 20733555
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The successful remission induction by sorafenib and long-term complete remission in a FLT3-ITD-positive patient with a refractory acute erythroid leukemia and abnormal cytogenetics.
    Mori M; Sprague J
    Leuk Res; 2012 Jan; 36(1):e1-3. PubMed ID: 21996560
    [No Abstract]   [Full Text] [Related]  

  • 16. Sorafenib as treatment for relapsed or refractory pediatric acute myelogenous leukemia.
    Watt TC; Cooper T
    Pediatr Blood Cancer; 2012 Oct; 59(4):756-7. PubMed ID: 22052552
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Investigational drugs targeting FLT3 for leukemia.
    Ustun C; DeRemer DL; Jillella AP; Bhalla KN
    Expert Opin Investig Drugs; 2009 Oct; 18(10):1445-56. PubMed ID: 19671038
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Sorafenib-induced hepatic encephalopathy.
    Marks AB; Gerard R; Fournier P; Coupe P; Gautier S
    Ann Pharmacother; 2009 Dec; 43(12):2121. PubMed ID: 19861429
    [No Abstract]   [Full Text] [Related]  

  • 19. Prognostic significance of CEBPA mutations in a large cohort of younger adult patients with acute myeloid leukemia: impact of double CEBPA mutations and the interaction with FLT3 and NPM1 mutations.
    Green CL; Koo KK; Hills RK; Burnett AK; Linch DC; Gale RE
    J Clin Oncol; 2010 Jun; 28(16):2739-47. PubMed ID: 20439648
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Detection of point mutation at second tyrosine kinase domain of FLT3 gene in acute myeloid leukemia].
    Wang LH; Wang M; Zhou CL; Chen S; Zhang XW; Xing HY; Wang JX
    Zhonghua Xue Ye Xue Za Zhi; 2005 Jun; 26(6):335-8. PubMed ID: 16185475
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.